• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>British Journal of Cancer >Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients
【2h】

Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) ± folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients

机译：奥沙利铂联合5-氟尿嘧啶（5-FU）±亚叶酸对481名耐5-FU的晚期大肠癌患者有同情心的人群的疗效预测因素

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin®) + 5-fluorouracil (5-FU) ± folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status ≤ 2, ≥ 3 involved sites, and ≥ 2 prior lines of chemotherapy, received oxaliplatin + 5-FU ± FA. Prognostic factors associated with overall response rate (ORR), time to progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The ORR was 16% (95% CI: 13–20), the median TTP was 4.2 months (95% CI: 3.4–4.6), and the median OS was 9.6 months (95% CI: 8.6–10.6). The multivariate analysis indicated poor (≥ 2 WHO) performance status (PS), a large number of prior chemotherapy regimens (≥ 3), a low baseline haemoglobin level (< 10 g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated (P< 0.05) with a lower ORR. Sex (male), number of organs involved (≥3) and alkaline phosphatase (AP) level (≥ 2 × the upper limit of normal) were associated (P< 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU ± FA treatment in 5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens. © 2001 Cancer Research Campaign
机译：使用奥沙利铂（Eloxatin®）+ 5-氟尿嘧啶（5-FU）±亚叶酸（FA）对从两个有同情心使用计划中收集的患者数据进行了统计分析，以确定基于奥沙利铂的抢救治疗的预测因素患有5-FU耐药的晚期大肠癌（ACRC）。 481例5-FU耐药的ACRC患者接受了奥沙利铂+ 5-FU±FA，大多数患者的工作状态≤2，≥3受累部位和≥2先前的化疗方案。使用单因素和多因素logistic和/或Cox比例风险分析确定与总缓解率（ORR），进展时间（TTP）和总生存期（OS）相关的预后因素。 ORR为16％（95％CI：13–20），中位TTP为4.2个月（95％CI：3.4–4.6），中位OS​​为9.6个月（95％CI：8.6-10.6）。多元分析表明，表现状态（PS）差（≥2 WHO），先前的大量化疗方案（≥3），基线血红蛋白水平低（<10μg/ dl）和每三周一次（相对于每两周一次）进行治疗与较低的ORR显着相关（P <0.05）。性别（男性），受累器官数量（≥3）和碱性磷酸酶（AP）水平（≥2×正常上限）与TTP较短相关（P <0.05）。 PS差，所涉及的大量器官和AP升高独立且与较短的OS显着相关。我们的分析确定了奥沙利铂+ 5-FU±FA治疗对5-FU耐药的ACRC患者的疗效与与PS，疾病范围和既往治疗方案数相关的基线预后因素之间的关系。 ©2001癌症研究运动

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号